Emcure Pharma Q3 Profit Jumps 50% to ₹230.5 Cr, Revenue Up 20.4%; Stock Gives Up Gains

• Emcure Pharmaceuticals reported a 50% year-on-year jump in consolidated net profit to ₹230.5 crore for the December quarter.
• Revenue from operations increased by 20.4% to ₹2,363 crore, driven by strong growth in both domestic and international markets.
• EBITDA climbed 39% to ₹493 crore, with operating margin expanding to 20.8% from 18% last year.
• Profit growth was fueled by strong traction in key therapies in India (up 15.4%) and sustained momentum in overseas markets (up 24.5%).
• The company launched Poviztra in partnership with Novo Nordisk, strengthening its presence in the weight management segment, but faced a one-time ₹38 crore hit from new labor code costs.